Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 6,319,192

« Back to Dashboard

Which drugs does patent 6,319,192 protect, and when does it expire?

Patent 6,319,192 protects CETROTIDE and is included in one NDA.

This patent has twenty-five patent family members in twenty-two countries.

Summary for Patent: 6,319,192

Title: Method for the treatment of fertility disorders
Abstract:An improvement to the method of intrauterine insemination by the administration of luteinizing hormone-releasing hormone antagonists (LHRH antagonists).
Inventor(s): Engel; Jurgen (Alzenau, DE), Riethmuller-Winzen; Hilde (Frankfurt, DE), Reissmann; Thomas (Frankfurt, DE)
Assignee: Zentaris AG (Frankfurt am Main, DE)
Application Number:09/296,610
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 2000RXYesYes6,319,192► Subscribe PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 2000DISCNNoNo6,319,192► Subscribe PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,319,192

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Czech Republic20003766► Subscribe
Germany69912422► Subscribe
Czech Republic301912► Subscribe
Denmark1082129► Subscribe
European Patent Office1082129► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc